share_log

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Benzinga ·  Nov 15 18:07  · Ratings

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $135 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment